Antibody News and Research

RSS

An antibody is a blood protein that is produced in response to and counteracts an antigen. Antibodies are produced in response to disease and help the body fight against the particular disease. In this way, antibodies help the body develop an immunity to disease.

Study highlights role of tumor-infiltrating B cells, plasma cells in cancer development and treatment outcomes

Through extensive single-cell analysis, researchers at The University of Texas MD Anderson Cancer Center have created a spatial map of tumor-infiltrating B cells and plasma cells in early-stage lung cancers, highlighting previously unappreciated roles these immune cells play in tumor development and treatment outcomes.

13 Sep 2022

Efficacy and safety of monoclonal antibodies against SARS-CoV-2 during pregnancy

In an article published in the journal Expert Opinion on Drug Safety, scientists have described the safety and efficacy profiles of anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) monoclonal antibodies in pregnant women with coronavirus disease 2019 (COVID-19).

13 Sep 2022

Altered T-cell response in hemodialysis patients following third COVID-19 vaccine dose

Scientists define the immune responses against COVID-19 in HD patients who received three mRNA COVID-19 vaccine doses.

13 Sep 2022

New drug marks cancer cells for destruction by the immune system

Tumor cells are notoriously good at evading the human immune system; they put up physical walls, wear disguises and handcuff the immune system with molecular tricks.

13 Sep 2022

Trastuzumab deruxtecan treatment maintains quality of life in HER2-low metastatic breast cancer patients

Patients who received trastuzumab deruxtecan (T-DXd) for human epidermal growth factor receptor 2 (HER2)-low metastatic breast cancer reported that the treatment maintained their quality of life (QoL) compared to conventional chemotherapy, according to results presented today by researchers from The University of Texas MD Anderson Cancer Center at the European Society for Medical Oncology Congress 2022.

13 Sep 2022

Transplacental passage of specific IgG in maternal SARS-CoV-2 infection

Researchers analyzed antibody profiles of mothers infected with SARS-CoV-2 and their offspring.

13 Sep 2022

MSK researchers reveal a promising treatment option for bladder cancer patients

Researchers from Memorial Sloan Kettering Cancer Center (MSK) shared a promising treatment option for bladder cancer patients today at The European Society for Medical Oncology (ESMO) Congress 2022.

13 Sep 2022

The impact of the infant gut microbiome on vaccine efficacy

A new study reports the effect of the infant gut microbiome on vaccine efficacy.

13 Sep 2022

Mucosal vaccination triggers superior T cell response against SARS-CoV-2 variants

In a recent study posted to the bioRxiv* server, researchers in Singapore and the United States demonstrated that intranasal (I.N.) delivery of a mucosal severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination triggered a superior T cell response compared to an equivalent dose of antigen delivered by the subcutaneous (S.C.) route.

12 Sep 2022

Antibiotics accelerate metastatic bone growth in mice with melanoma by depleting intestinal flora

The use of broad-spectrum antibiotics in mice with malignant melanoma, an aggressive form of skin cancer, accelerated their metastatic bone growth, likely because the drugs depleted the mice's intestinal flora and weakened their immune response, according to a new study by researchers at Emory University in Atlanta.

12 Sep 2022

Vaccines that induce mucosal immunity against SARS-CoV-2 are needed

In a recent study posted to the medRxiv* preprint server, researchers in the United Kingdom studied assessed plasma and nasal antibody (Ab) responses induced after a year of coronavirus disease 2019 (COVID-19)-associated hospitalization and the potential boost by subsequent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccinations in the United Kingdom (UK).

12 Sep 2022

N-dihydrogalactochitosan shows promise as a mucosal vaccine adjuvant against SARS-CoV-2

In a recent study posted to the bioRxiv* server, researchers in the United States demonstrated the efficacy of a novel biopolymer, N-dihydrogalactochitosan (GC), as an adjuvant for next-generation mucosal coronavirus disease 2019 (COVID-19) vaccine.

12 Sep 2022

New cold perfusion approach to isolate hepatic stellate cells from fatty liver-associated tumors

Obesity can give rise to a variety of health concerns. Nonalcoholic steatohepatitis (NASH) - a type of fatty liver disease that might progress to cancer - is particularly prevalent among obese people.

12 Sep 2022

Are antibodies induced by historic smallpox vaccination cross-reactive with the monkeypox virus?

esearchers measured the monkeypox virus-neutralizing antibodies produced by the vaccinia virus vaccine, modified vaccinia virus Ankara vaccine, and monkeypox virus to understand the efficacy of the MVA-Bavarian Nordic vaccine currently being used against monkeypox.

12 Sep 2022

Did the US jump the gun with the new omicron-targeted vaccines?

Last month, the FDA authorized omicron-specific vaccines, accompanied by breathless science-by-press release and a media blitz.

12 Sep 2022

Dissecting vaccinia virus and monkeypox virus-specific T cell responses in humans

In a new study, a team of researchers studied different antigens targeted by vaccinia virus (VACV)- and monkeypox virus (MPXV)-specific T cells.

12 Sep 2022

The ongoing 2022 West Nile virus transmission season in Italy

A recent article described the seasonal transmission of the West Nile virus in 2022 and compared the human cases reported in June-July 2022 with the reports in 2018.

12 Sep 2022

SARS-CoV-2 Omicron BA.4.6 resistant to many therapeutic monoclonal antibodies in clinical use

In a recent study posted to the bioRxiv* preprint server, researchers in Taiwan and the United States explore the resistance of a newly emergent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron sub-variant BA.4.6 to the therapeutic monoclonal antibodies currently being used to treat coronavirus disease 2019 (COVID-19).

12 Sep 2022

Tumor-infiltrating lymphocytes therapy treats cancers at a large scale

A novel treatment strategy with personalized cell therapy significantly improves progression-free survival compared to standard immunotherapy in patients with advanced melanoma, according to ground-breaking results reported at the ESMO Congress 2022 from the phase 3 M14TIL trial.

12 Sep 2022

Pollutant particles in the air trigger lung cancer in non-smokers

A new mechanism has been identified through which very small pollutant particles in the air may trigger lung cancer in people who have never smoked, paving the way to new prevention approaches and development of therapies, according to late-breaking data [to be] reported at the ESMO Congress 2022 by scientists of the Francis Crick Institute and University College London, funded by Cancer Research UK. The particles, which are typically found in vehicle exhaust and smoke from fossil fuels, are associated with non-small cell lung cancer (NSCLC) risk, accounting for over 250,000 lung cancer deaths globally per year.

12 Sep 2022

Antibody News and Research

Further Reading

Study highlights role of tumor-infiltrating B cells, plasma cells in cancer development and treatment outcomes

Efficacy and safety of monoclonal antibodies against SARS-CoV-2 during pregnancy

Altered T-cell response in hemodialysis patients following third COVID-19 vaccine dose

New drug marks cancer cells for destruction by the immune system

Trastuzumab deruxtecan treatment maintains quality of life in HER2-low metastatic breast cancer patients

Transplacental passage of specific IgG in maternal SARS-CoV-2 infection

MSK researchers reveal a promising treatment option for bladder cancer patients

The impact of the infant gut microbiome on vaccine efficacy

Mucosal vaccination triggers superior T cell response against SARS-CoV-2 variants

Antibiotics accelerate metastatic bone growth in mice with melanoma by depleting intestinal flora

Vaccines that induce mucosal immunity against SARS-CoV-2 are needed

N-dihydrogalactochitosan shows promise as a mucosal vaccine adjuvant against SARS-CoV-2

New cold perfusion approach to isolate hepatic stellate cells from fatty liver-associated tumors

Are antibodies induced by historic smallpox vaccination cross-reactive with the monkeypox virus?

Did the US jump the gun with the new omicron-targeted vaccines?

Dissecting vaccinia virus and monkeypox virus-specific T cell responses in humans

The ongoing 2022 West Nile virus transmission season in Italy

SARS-CoV-2 Omicron BA.4.6 resistant to many therapeutic monoclonal antibodies in clinical use

Tumor-infiltrating lymphocytes therapy treats cancers at a large scale

Pollutant particles in the air trigger lung cancer in non-smokers

How to make hybridoma-based antibody discovery more efficient eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo